[1] | Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362:1605-17. | [2] | Nakagawa T, Masuda A, Toyama H, Shiomi H, Zen Y, Sofue K, et al. Smoking Status and the Incidence of Pancreatic Cancer Concomitant With Intraductal Papillary Mucinous Neoplasm. Pancreas 2018; 46:1. | [3] | Lu PY, Shu L, Shen SS, Chen XJ, Zhang XY. Dietary Patterns and Pancreatic Cancer Risk: A Meta-Analysis. Nutrients 2017; 9:38. | [4] | Mayerle J, Kalthoff H, Reszka R, Kamlage B, Peter E, Schniewind B, et al. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. Gut Jan 2018; 67:128-37. | [5] | Jang WI, Kim MS, Kang SH, Jo AJ, Kim YJ, Tchoe HJ, et al. Association between metformin use and mortality in patients with type 2 diabetes mellitus and localized resectable pancreatic cancer: a nationwide population-based study in korea. Oncotarget 2017; 8:9587-96. | [6] | Malvezzi M, Bertuccio P, Levi F, La VC, Negri E. European cancer mortality predictions for the year 2012. Ann Oncol 2013; 24:792. | [7] | Siegel RL, Ma J, Zou Z, Jemal A. Cancer Statistics 2014. CA Cancer J Clin 2014; 64:9-29. | [8] | Gillen S, Schuster T, Meyer ZBC, Friess H, Kleeff J. Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages. PLoS Med 2010; 7:e1000267. | [9] | Moutardier V, Magnin V, Turrini O, Viret F, Hennekinnemucci S, Gon?alves A, et al. Assessment of pathologic response after preoperative chemoradiotherapy and surgery in pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 2004; 60:437-43. | [10] | Zorbas G, Samaras T. A study of the sink effect by blood vessels in radiofrequency ablation. Comput Biol Med 2015; 57:182-86. | [11] | Edd JF, Horowitz L, Davalos RV, Mir LM. In vivo results of a new focal tissue ablation technique: irreversible electroporation. IEEE Trans Biomed Eng 2006; 53:1409-15. | [12] | Vogel JA, Van VE, Agnass P, Crezee J, Dijk F, Verheij J, et al. Time-Dependent Impact of Irreversible Electroporation on Pancreas, Liver, Blood Vessels and Nerves: A Systematic Review of Experimental Studies. Plos One 2016; 11:e0166987. | [13] | Niessen C, Thumann S, Beyer L, Pregler B, Kramer J, Lang S, et al. Percutaneous Irreversible Electroporation: Long-term survival analysis of 71 patients with inoperable malignant hepatic tumors. Sci Rep 2017; 7:43687. | [14] | Canvasser NE, Sorokin I, Lay AH, Morgan MSC, Ozayar A, Trimmer C, et al. Irreversible electroporation of small renal masses: suboptimal oncologic efficacy in an early series. World J Urol 2017; 35:1549-55. | [15] | Beyer LP, Pregler B, Nie?en C, Michalik K, Haimerl M, Stroszczynski C, et al. Percutaneous irreversible electroporation (IRE) of prostate cancer: Contrast-enhanced ultrasound (CEUS) findings during follow up. Clin Hemorheol Microcirc 2016; 64:501-06. | [16] | Yan L, Chen YL, Su M, Liu T, Xu K, Liang F, et al. A Single-institution Experience with Open Irreversible Electroporation for Locally Advanced Pancreatic Carcinoma. Chin Med J (Engl) 2016; 129:2920. | [17] | Belfiore MP, Ronza FM, Romano F, Ianniello GP, De Lucia G, Gallo C, et al. Percutaneous CT-guided irreversible electroporation followed by chemotherapy as a novel neoadjuvant protocol in locally advanced pancreatic cancer: Our preliminary experience. Int J Surg 2015; 21 Suppl 1: S34-9. | [18] | Liberati A, Altman DG, Tetzlaff J, Mulrow C, G?tzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 6:e1-e34. | [19] | Cochran WG. The Combination of Estimates from Different Experiments. Biometrics 1954; 10:101-29. | [20] | Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2010; 21:1539-58. | [21] | Bendavid E, Ahmed M, Faroja M, Moussa M, Wandel A, Sosna J, et al. Irreversible electroporation: treatment effect is susceptible to local environment and tissue properties. Radiology 2013; 269:738-47. | [22] | Philips P, Yan L, Li S, Hill CRS, Martin RC. Efficacy of irreversible electroporation in human pancreatic adenocarcinoma: advanced murine model. Mol Ther Methods Clin Dev 2015; 2:15001. | [23] | Bagla S, Papadouris D. Percutaneous irreversible electroporation of surgically unresectable pancreatic cancer: a case report. Journal of Vascular & Interventional Radiology Jvir 2012; 23:142-5. | [24] | Scheffer HJ, Vroomen LG, de Jong MC, Melenhorst MC, Zonderhuis BM, Daams F, et al. Ablation of Locally Advanced Pancreatic Cancer with Percutaneous Irreversible Electroporation: Results of the Phase I/II PANFIRE Study. Radiology 2016; 18:152835. | [25] | Chiu D, Niu L, Mu F, Peng X, Zhou L, Li H, et al. The experimental study for efficacy and safety of pancreatic cryosurgery. Cryobiology Jun 2010; 60:281-6. | [26] | Joo Kyung Park, Woo Hyun Paik, Ji Kon Ryu, Yong-Tae Kim, Youn Joo Kim, Jaihwan Kim, et al. Clinical Significance and Revisiting the Meaning of CA 19-9 Blood Level Before and After the Treatment of Pancreatic Ductal Adenocarcinoma: Analysis of 1,446 Patients from the Pancreatic Cancer Cohort in a Single Institution. Plos One 2013; 8:e78977. |
|